Evidence map›Paper›PMID 39390760›Full record

ArticleClinical and translational medicine2024

Reduction of myeloid-derived suppressor cells in prostate cancer murine models and patients following white button mushroom treatment.

Xiaoqiang Wang, Shoubao Ma, Przemyslaw Twardowski, Clayton Lau, Yin S Chan, Kelly Wong, Sai Xiao, Jinhui Wang, Xiwei Wu, Paul Frankel and 7 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04519879 (A Randomized Phase 2 Trial of White Button Mushroom Supplement in Patients With Biochemically Recurrent Prostate Cancer Following Local Therapy and in Therapy Na?ve Patients With Favorable Risk Prostate Cancer Undergoing Active Surveillance), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04519879 phase2suspendednot on this map

A Randomized Phase 2 Trial of White Button Mushroom Supplement in Patients With Biochemically Recurrent Prostate Cancer Following Local Therapy and in Therapy Na?ve Patients With Favorable Risk Prostate Cancer Undergoing Active Surveillance

TypeinterventionalSponsorCity of Hope Medical CenterRan2021 to 2026Enrolled133ConditionsProstate Adenocarcinoma, PSA Failure, PSA Progression, Recurrent Prostate CarcinomaArmsClinical Observation, Patient Observation, Questionnaire Administration, White Button Mushroom Extract
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Bolstering CD8Biology · 2025
    Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Xiaoqiang WangDepartment of Cancer Biology & Molecular Medicine, Beckman Research Institute, City of Hope, Duarte, California, USA.
Shoubao MaDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Przemyslaw TwardowskiDepartment of Urology and Urologic Oncology, Providence Saint John's Cancer Institute, Santa Monica, California, USA.
Clayton LauDepartment of Surgery, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Yin S ChanDepartment of Cancer Biology & Molecular Medicine, Beckman Research Institute, City of Hope, Duarte, California, USA.
Kelly WongDepartment of Cancer Biology & Molecular Medicine, Beckman Research Institute, City of Hope, Duarte, California, USA.
Sai XiaoDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Jinhui WangIntegrative Genomics Core, Beckman Research Institute, City of Hope, Monrovia, California, USA.
Xiwei WuDepartment of Computational and Quantitative Medicine, Beckman Research Institute, City of Hope, Duarte, California, USA.
Paul FrankelDepartment of Computational and Quantitative Medicine, Beckman Research Institute, City of Hope, Duarte, California, USA.
Timothy G WilsonDepartment of Urology and Urologic Oncology, Providence Saint John's Cancer Institute, Santa Monica, California, USA.
Timothy W SynoldDepartment of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Cary PresantDepartment of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Tanya DorffDepartment of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Jianhua YuDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
David SadavaDepartment of Cancer Biology & Molecular Medicine, Beckman Research Institute, City of Hope, Duarte, California, USA.
Shiuan ChenDepartment of Cancer Biology & Molecular Medicine, Beckman Research Institute, City of Hope, Duarte, California, USA.ORCID 0000-0002-4482-6926

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI John Charles Williams · 1985 to 2026
$86.3M
(PQ11) Immune modulatory effects of white button mushroom in prostate cancer - A translational researchR01CA227230 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, SHIUAN, LAU, CLAYTON · 2019 to 2023
$3.3M
NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA227230NIH HHS CA227230
6 · The paper itself

Abstract

backgroundIn a previously reported Phase I trial, we observed therapy-associated declines in circulating myeloid-derived suppressor cells (MDSCs) with the administration of white button mushroom (WBM) tablets in prostate cancer (PCa) patients. These observations led us to hypothesise that WBM could mitigate PCa progression by suppressing MDSCs.

methodsWe performed bidirectional translational research to examine the immunomodulatory effects of WBM consumption in both syngeneic murine PCa models and patients with PCa participating in an ongoing randomised Phase II trial (NCT04519879).

resultsIn murine models, WBM treatment significantly suppressed tumour growth with a reduction in both the number and function of MDSCs, which in turn promoted antitumour immune responses mediated by T cells and natural killer (NK) cells. In patients, after consumption of WBM tablets for 3 months, we observed a decline in circulating polymorphonuclear MDSCs (PMN-MDSCs), along with an increase in cytotoxic CD8

conclusionOur results from PCa murine models and patients provide mechanistic insights into the immunomodulatory effects of WBM and provide a scientific foundation for WBM as a nutraceutical intervention to delay or prevent PCa progression. HIGHLIGHTS: White button mushroom (WBM) treatment resulted in a reduction in pro-tumoural MDSCs, notably polymorphonuclear MDSCs (PMN-MDSCs), along with activation of anti-tumoural T and NK cells. Human single immune cell gene expression profiling shed light on the molecular alterations induced by WBM, specifically on PMN-MDSCs. A proof-of-concept study combining WBM with PD-1 blockade in murine models revealed an additive effect on tumour regression and survival outcomes, highlighting the clinical relevance of WBM in cancer management.

Indexed as

Myeloid-Derived Suppressor CellsProstatic NeoplasmsAgaricalesAnimalsClinical Trials, Phase II as TopicDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLclinical trialmyeloid‐derived suppressor cells (MDSCs)nutraceutical interventionprostate cancersingle immune cell profilingwhite button mushroom

Identifiers

PMID39390760
PMCPMC11467013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.